Skip to main content

Advertisement

SpringerLink
Log in

The renal effects of ALK inhibitors

  • REVIEW
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Anaplastic lymphoma kinase 1 (ALK-1) is a member of the insulin receptor tyrosine kinase family. In clinical practice, three small molecule inhibitors of ALK-1 are used, namely crizotinib, ceritinib and alectinib. Several more agents are in active pre-clinical and clinical studies. Crizotinib is approved for the treatment of advanced ALK-positive non-small cell lung cancer (NSCLC). According to the package insert and published literature, treatment with crizotinib appears to be associated with kidney failure as well as an increased risk for the development and progression of renal cysts. In addition, this agent is associated with development of peripheral edema and rare electrolyte disorders. This review focuses on the adverse renal effects of Crizotinib in clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Orscheschek K, Merz H, Hell J, Binder T, Bartels H, Feller AC (1995) Large-cell anaplastic lymphoma-specific translocation (t[2;5] [p23;q35]) in Hodgkin’s disease: indication of a common pathogenesis? Lancet 345(8942):87–90

    Article  CAS  PubMed  Google Scholar 

  2. Ullrich A, Schlessinger J (1990) Signal transduction by receptors with tyrosine kinase activity. Cell 61(2):203–212

    Article  CAS  PubMed  Google Scholar 

  3. Roskoski R Jr (2013) Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition. Pharmacol Res 68(1):68–94

    Article  CAS  PubMed  Google Scholar 

  4. Bullrich F, Morris SW, Hummel M, Pileri S, Stein H, Croce CM (1994) Nucleophosmin (NPM) gene rearrangements in Ki-1-positive lymphomas. Cancer Res 54(11):2873–2877

    CAS  PubMed  Google Scholar 

  5. Pillay K, Govender D, Chetty R (2002) ALK protein expression in rhabdomyosarcomas. Histopathology 41(5):461–467

    Article  CAS  PubMed  Google Scholar 

  6. Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M et al (2008) Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455(7215):971–974

    Article  CAS  PubMed  Google Scholar 

  7. Shinmura K, Kageyama S, Tao H, Bunai T, Suzuki M, Kamo T et al (2008) EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. Lung Cancer 61(2):163–169

    Article  PubMed  Google Scholar 

  8. American Cancer Society (2015) Cancer facts & figures 2015. American Cancer Society, Atlanta

    Google Scholar 

  9. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E386

    Article  CAS  PubMed  Google Scholar 

  10. Ettinger D, Akerley W, Bepler G, Blum M, Chang A, Cheney R et al (2010) Non-small cell lung cancer. J Natl Compr Cancer Netw 8:740–801

    CAS  Google Scholar 

  11. Larsen J, Cascon T, Gerber D, Heymach J, Minna J (2011) Targeted therapies for lung cancer: clinical experience and novel agents. Cancer J 17:512–527

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S et al (2007) Identification of the transforming EML4-ALK fusion gene in non-smal-cell lung cancer. Nature 448:561–566

    Article  CAS  PubMed  Google Scholar 

  13. Mano H (2008) Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer. Cancer Sci 99:2349–2355

    Article  CAS  PubMed  Google Scholar 

  14. Horn L, Pao W (2009) EML4-ALK: honing in on a new target in non-small-cell lung cancer. J Clin Oncol 27:4232–4235

    Article  CAS  PubMed  Google Scholar 

  15. Shaw AT, Yeap BY, Mino-Kenudson M et al (2009) Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27:4247–4253

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Camidge DR, Doebele RC (2012) Treating ALK-positive lung cancer—early successes and future challenges. Nat Rev Clin Oncol 9:268–277

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Blackhall FH, Peters S, Bubendorf L et al (2014) Prevalence and clinical outcomes for patients with ALK-positive resected stage I-III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project. J Clin Oncol 32:2780–2787

    Article  PubMed  Google Scholar 

  18. Sullivan I, Planchard D (2016) ALK inhibitors in non-small cell lung cancer: the latest evidence and developments. Ther Adv Med Oncol 8(1):32–47

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Solomon B, Mok T, Kim D, Wu Y, Nakagawa K, Mekhail T et al (2014) First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371:2167–2177

    Article  PubMed  Google Scholar 

  20. Camidge D, Bang Y, Kwak E, Iafrate A, Varella-Garcia M, Fox S et al (2012) Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 13:1011–1019

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Christensen JG, Zou HY, Arango ME et al (2007) Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 6(12 Pt 1):3314

    Article  CAS  PubMed  Google Scholar 

  22. Li C, Alvey C, Bello A et al. (2011) Pharmacokinetics (PK) of crizotinib (PF- 02341066) in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors. J Clin Oncol 29(Suppl):abstract e13065

  23. FDA (2011) Prescribing information. Xalkori (crizotinib) or capsules. Pfizer labs, New York, Available from: http://www.accessdata.fda.gov/ drugsatfdadocs/label/2011/202570s000lbl.pdf. [Last accessed on 2013 Mar 6

    Google Scholar 

  24. US Food and Drug Administration (2013) Approval history XALKORI, NDA no. 202570, http://labeling.pfizer.com/showlabeling.aspx?id=676. Accessed November 15, 2013

  25. Ou SHI, Salgia R, Clark J (2010) Comparison of crizotinib (PF-02341066) pharmacokinetics between Asian and non-Asian patients with advanced malignancies. J Thorac Oncol 5(Suppl 5):S382

    Google Scholar 

  26. Camidge DR, Bang Y, Kwak EL, et al. (2011) Progression-free survival (PFS) from a phase 1 study of crizotinib (PF-02341066) in patients with ALK positive non-small cell lung cancer (NSCLC). J Clin Oncol 29(Suppl):abstract 2501

  27. Tabernero J, Elez M, Herranz M et al (2014) A pharmacodynamics/pharmacokinetic study of Ficlatuzumab in patients with advanced solid tumors and liver metastases. Clin Cancer Res 20:2793–2804

    Article  CAS  PubMed  Google Scholar 

  28. Brosnan EM, Weickhardt AJ, Lu X, Maxon DA, Barón AE, Chonchol M (2013) Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small-cell lung cancer treated with the ALK inhibitor crizotinib. Cancer. doi:10.1002/cncr.2847

    PubMed  PubMed Central  Google Scholar 

  29. Murata K, Baumann NA, Saenger AK, Larson TS, Rule AD, Lieske JC (2011) Relative performance of the MDRD and CKD-EPI equations for estimating glomerular filtration rate among patients with varied clinical presentations. Clin J Am Soc Nephrol 6:1963–1972

    Article  PubMed  PubMed Central  Google Scholar 

  30. Earley A, Miskulin D, Lamb EJ, Levey AS, Uhlig K (2012) Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review. Ann Intern Med 156:785–795

    Article  PubMed  Google Scholar 

  31. Gastaud L, Ambrosetti D, Otto J, Marquette CH, Coutts M, Hofman P et al (2013) Acute kidney injury following crizotinib administration for non-small-cell lung adenocarcinoma. Lung Cancer 82:362–364

    Article  PubMed  Google Scholar 

  32. Martorell PM, Alvaro MH, Salguero MAS, Molla AI (2014) Crizotinib and renal insufficiency: a case report and review of the literature. Lung Cancer 84:310–313

    Article  Google Scholar 

  33. Ciarimboli G, Lancaster CS, Schlatter E et al (2012) Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients. Clin Cancer Res 18:1101–1108

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Breyer MD, Qi Z (2010) Better nephrology for mice–and man. Kidney Int 77:487–489

    Article  PubMed  Google Scholar 

  35. Urakami Y, Kimura N, Okuda M, Inui K (2004) Creatinine transport by basolateral organic cation transporter hOCT2 in the human kidney. Pharm Res 21:976–981

    Article  CAS  PubMed  Google Scholar 

  36. Burgess E, Blair A, Krichman K, Cutler RE (1982) Inhibition of renal creatinine secretion by cimetidine in humans. Ren Physiol 5:27–30

    CAS  PubMed  Google Scholar 

  37. van Acker BA, Koomen GC, Koopman MG, de Waart DR, Arisz L (1992) Creatinine clearance during cimetidine administration for measurement of glomerular filtration rate. Lancet 340:1326–1329

    Article  PubMed  Google Scholar 

  38. Kastrup J, Petersen P, Bartram R, Hansen JM (1985) The effect of trimethoprim on serum creatinine. Br J Urol 57:265–268

    Article  CAS  PubMed  Google Scholar 

  39. Myre SA, McCann J, First MR, Cluxton RJ Jr (1987) Effect of trimethoprim on serum creatinine in healthy and chronic renal failure volunteers. Ther Drug Monit 9:161–165

    Article  CAS  PubMed  Google Scholar 

  40. Naderer O, Nafziger AN, Bertino JS Jr (1997) Effects of moderate-dose versus high-dose trimethoprim on serum creatinine and creatinine clearance and adverse reactions. Antimicrob Agents Chemother 41:2466–2470

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Opravil M, Keusch G, Luthy R (1993) Pyrimethamine inhibits renal secretion of creatinine. Antimicrob Agents Chemother 37:1056–1060

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Camidge DR, Brosnan EM, DeSilva C, Koo PJ, Chonchol M (2014) Crizotinib effects on creatinine and non-creatinine-based measures of glomerular filtration rate. J Thorac Oncol 9(11):1634–1637

    Article  CAS  PubMed  Google Scholar 

  43. Whelan TF (2010) Guidelines on the management of renal cyst disease. Can Urol Assoc J 4:98–99

    Article  PubMed  PubMed Central  Google Scholar 

  44. Carrim ZI, Murchison JT (2003) The prevalence of simple renal and hepatic cysts detected by spiral computed tomography. Clin Radiol 58:626–629

    Article  CAS  PubMed  Google Scholar 

  45. Minor LD, Picken MM, Campbell SC (2003) Pp. 170–171 in AUA update series (Vol. 22): benign renal tumors. American Urological Association, Houston, TX. Whelan TF. Guidelines on the management of renal cyst disease. Can Urol Assoc J. 2010;4:98–99

  46. Bosniak MA (1986) The current radiological approach to renal cysts. Radiology 158:1–10

    Article  CAS  PubMed  Google Scholar 

  47. Israel GM, Bosniak AM (2005) An update of the Bosniak renal cyst classification system. Urology 66:484–488

    Article  PubMed  Google Scholar 

  48. Curry NS, Cochran ST, Bissada NK (2000) Cystic renal masses: accurate Bosniak classification requires adequate renal CT. AJR Am J Roentgenol 175:339–342

    Article  CAS  PubMed  Google Scholar 

  49. Eknoyan G (2009) A clinical view of simple and complex renal cysts. J Am Soc Nephrol 20:1874–1876

    Article  PubMed  Google Scholar 

  50. Mosharafa AA (2008) Prevalence of renal cysts in a Middle-Eastern population: an evaluation of characteristics and risk factors. BJU Int 101:736–738

    Article  PubMed  Google Scholar 

  51. Dong S, Patel N, Kundavaram C, Glassman D, Bagley D (2011) A contemporary study of renal cysts in a representative US population. Presented at the New England and Mid-Atlantic Sections of the American Urological Association 2011 Joint Annual Meeting, Orlando, FL, 3–5 November 2011. Available at http://meeting.neaua.org/abstracts/2011/6.cgi (accessed 4 November 2014)

  52. Lin YT, Wang YF, Yang JC, Yu CJ, Wu SG, Shih JY et al (2014) Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer. J Thorac Oncol 9(11):1720–1725

    Article  CAS  PubMed  Google Scholar 

  53. Schnell P, Bartlett CH, Solomon BJ, Tassell V, Shaw AT, de Pas T, Lee SH, Lee GK, Tanaka K, Tan W, Tang Y, Wilner KD, Safferman A, Han JY (2015) Complex renal cysts associated with crizotinib treatment. Cancer Med 4(6):887–896

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. XALKORI U.S (2014) Physician prescribing information. Available at http://labeling.pfizer.com/ShowLabeling.aspx?id=676. Accessed May 15, 2014

  55. Shaw AT, Kim DW, Nakagawa K et al (2013) Crizotinib vs chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368(25):2385

    Article  CAS  PubMed  Google Scholar 

  56. Souteyrand P, Burtey S, Barlesi F (2015) Multicystic kidney disease: a complication of crizotinib. Diagn Interv Imaging 96(4):393–395

    Article  CAS  PubMed  Google Scholar 

  57. Sierra JR, Tsao MS (2011) c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol 3(Suppl 1):S21–S35

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Pisters LL, El-Naggar AK, Luo W, Malpica A, Lin SH (1997) C-met protooncogene expression in benign and malignant human renal tissues. J Urol 158(3 Pt 1):724–728

    Article  CAS  PubMed  Google Scholar 

  59. Horie S, Higashihara E, Nutahara K, Mikami Y, Okubo A, Kano M et al (1994) Mediation of renal cyst formation by hepatocyte growth factor. Lancet 344:789–791

    Article  CAS  PubMed  Google Scholar 

  60. Konda R, Sato H, Hatafuku F, Nozawa T, Ioritani N, Fujioka T (2014) Expression of hepatocyte growth factor and its receptor C-met in acquired renal cystic disease associated with renal cell carcinoma. J Urol 171:2166–2170

    Article  Google Scholar 

  61. Zhou D, Tan RJ, Lin L, Zhou L, Liu Y (2013) Activation of hepatocyte growth factor receptor, c-met, in renal tubules is required for renoprotection after acute kidney injury. Kidney Int 84:509–520

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Qin S, Taglienti M, Cai L, Zhou J, Kreidberg JA (2012) c-Met and NF-kappaBdependent overexpression of Wnt7a and -7b and Pax2 promotes cystogenesis in polycystic kidney disease. J Am Soc Nephrol 23:1309–1318

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Cowley BD Jr, Rupp JC, Muessel MJ, Gattone VH 2nd (1997) Gender and the effect of gonadal hormones on the progression of inherited polycystic kidney disease in rats. Am J Kidney Dis 29(2):265–272

    Article  CAS  PubMed  Google Scholar 

  64. Jayapalan S, Saboorian MH, Edmunds JW, Aukema HM (2000) High dietary fat intake increases renal cyst disease progression in Han: SPRD-cy rats. J Nutr 130(9):2356–2360

    CAS  PubMed  Google Scholar 

  65. Weickhardt AJ, Rothman MS, Salian-Mehta S, Kiseljak-Vassiliades K, Oton AB, Doebele RC, Wierman ME, Camidge DR (2012) Rapid onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer 118(21):5302–5309

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nephrology, Monceau Park International Clinic Paris, Paris, France

    Hassan Izzedine

  2. Department of Nephrology, La Rabta Hospital, Tunis, Tunisia

    Rania Kheder El-Fekih

  3. Department of Nephrology, Yale University School of Medicine, New Haven, CT, 06520, USA

    Mark A. Perazella

Authors
  1. Hassan Izzedine
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rania Kheder El-Fekih
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mark A. Perazella
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hassan Izzedine.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Izzedine, H., El-Fekih, R.K. & Perazella, M.A. The renal effects of ALK inhibitors. Invest New Drugs 34, 643–649 (2016). https://doi.org/10.1007/s10637-016-0379-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-016-0379-y

Keywords

Search

Navigation